{"disease":{"id":"advanced-triple-negative-breast-cancer","name":"advanced triple negative breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05867251","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Avenzo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07391956","title":"Tier Palliative Care For Patients With Advanced Heart Failure or Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT04180371","title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"BicycleTx Limited","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT05768932","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"SillaJen, Inc.","has_results":false},{"nct_id":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT04332653","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"NeoImmuneTech","has_results":true},{"nct_id":"NCT04742959","title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT02936102","title":"A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":154,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06771609","title":"Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT01884285","title":"AZD8186 First Time In Patient Ascending Dose Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06878625","title":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03251378","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":true},{"nct_id":"NCT03333915","title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03667716","title":"COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT05227664","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT06849492","title":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06685796","title":"A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"BeBetter Med Inc","has_results":false},{"nct_id":"NCT01889238","title":"Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04408118","title":"First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT06799065","title":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Accent Therapeutics","has_results":false},{"nct_id":"NCT04691375","title":"A Study of PY314 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":86,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT05253053","title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT05252390","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":82,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04348916","title":"Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Oncorus, Inc.","has_results":false},{"nct_id":"NCT03254654","title":"Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02981303","title":"Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"HiberCell, Inc.","has_results":true},{"nct_id":"NCT05082259","title":"ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":61,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT07510802","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT07486089","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT04442126","title":"A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Numab Therapeutics AG","has_results":true},{"nct_id":"NCT05491083","title":"Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false},{"nct_id":"NCT05383196","title":"Onvansertib + Paclitaxel In TNBC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Antonio Giordano, MD","has_results":false},{"nct_id":"NCT02435680","title":"Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03654547","title":"Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT04424641","title":"A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":48,"lead_sponsor_name":"Genmab","has_results":true},{"nct_id":"NCT03292172","title":"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01676753","title":"Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Jo Chien","has_results":false},{"nct_id":"NCT05341492","title":"EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}